Know Cancer

forgot password

A Phase la Trial of Photodynamic Therapy With HPPH (2-1 (Hexyloxyethyl)-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx.

Phase 1
18 Years
Not Enrolling
Dysplasia, Carcinoma of the Oral Cavity, Carcinoma of the Oropharynx

Thank you

Trial Information

A Phase la Trial of Photodynamic Therapy With HPPH (2-1 (Hexyloxyethyl)-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx.

We propose to initiate a Phase 1 a clinical trial using HPPH and 665 nm light in patients
with cancer of the oral cavity and/or oropharynx, including lesions of moderate to severe
dysplasia, squamous carcinoma in situ and T1 squamous cells carcinoma. The study will employ
a fixed HPPH dose of 4 mg/m2 infused over 1 hour, and 24 hours later light doses escalating
from 100 J/cm2 to 125 and 140 J/cm2, respectively. The primary goal is the determination of
the maximally tolerated PDT dose. Preliminary evidence for PDT efficacy wil also be

Inclusion Criteria:

- Patients with moderate to severe dysplasia and/or squamous carcinoma-in-situ of the
oral cavity and/or oropharynx.

- Patients with T1 squamous cell carcinoma of the oral cavity and/or oropharynx.

- Patient may have primary and/or recurrent lesions to be treated.

- Diagnosis must confirmed by biopsy.

- Prior therapy of any type is allowed.

- Male or female patients at least 18 years old. Female patients must not be pregnant
and must be practicing a medically acceptable form of birth control, be sterile or
post-menopausal. Male patients should be using a medically acceptable form of birth
control or be sterile.

- Patients must have an ECOG score of 0-2 (Appendix A 1 ).

- Patient or legal representative must understand the investigational nature of this
study and sign an Independent Ethics Committee/Institutional Review Board approved
written informed consent form prior to receiving any study related procedure.

Exclusion Criteria:

- Patients with T2 or greater squamous cell carcinoma.

- True tongue base lesions (as determined by the treating physician).

- Patients with severe trismus that prevents adequate access to the lesion for
treatment light delivery (as determined by the treating physician).

- Porphyria or hypersensitivity to porphyrin or porphyrin-like compounds.

- Patients with impaired hepatic (alkaline phosphatase (hepatic) or SGOT;:3 times the
upper normal limits).

- Patients with minimal impairment of renal function (total serum bilirubin;: 2 mg/dl,
serum creatinine;: 2 mg/dl)

- Unwilling or unable to follow protocol requirements.

- Any condition which in the Investigator's opinion deems the patient an unsuitable
candidate to receive study drug and or light treatment.

- Patients on concurrent chemotherapy or radiation therapy or less than 4 weeks after
the last dose of chemotherapy or radiation therapy.

Inclusion of Women and Minorities:

- Both men and women and members of all races and ethnic groups are eligible for this

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:


Outcome Description:

To determine the maximally tolerated dose in the oral cavity and/or oropharynx of photodynamic therapy (PDT) using HPPH (2-1 (hexyloxyethyl)-2- devinylpyropheophorbide-a) and 665 nm light.

Outcome Time Frame:

6 weeks

Safety Issue:


Principal Investigator

Nestor Rigual, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Roswell Park Cancer Institute


United States: Food and Drug Administration

Study ID:

I 170910



Start Date:

June 2010

Completion Date:

Related Keywords:

  • Dysplasia
  • Carcinoma of the Oral Cavity
  • Carcinoma of the Oropharynx
  • Photodynamic Therapy
  • Oral dysplasia
  • oral cavity carcinoma
  • oropharynx carcinoma.
  • Carcinoma
  • Carcinoma in Situ
  • Hyperplasia
  • Oropharyngeal Neoplasms



Roswell Park Cancer Institute Buffalo, New York  14263